Corus Pharma

Corus Pharma
Based: Seattle
Founded: 2001

Why It's Fierce: Having raised $18.5 million from an elite group of investors that includes Bill Gates' personal VC fund four years ago, Corus Pharma remains an attractive outfit on the biotech scene. Much of that money is funding a Phase II trial of Corus 1020, an inhaled antibiotic designed for cystic fibrosis patients that won orphan drug status in 2002. An asthma drug, Corus 1030, is also well along the pipeline. CEO A. Bruce Montgomery, M.D., a veteran of both PathoGenesis and Genentech, has direct experience in the field of cystic fibrosis research.

What to look for: Phase II results are due soon.

Corus Pharma

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.